Innovating Works

filtrando por convocatoria: HORIZON-HLTH-2022-DISEASE-06-02-two-stage

Mostrando 1 al 20 de 25 resultados
MITI 2: Gut Microbiota-Induced Tregs for Inflammatory-Bowel-Disease (IBD) Immunotherapy (MITI2) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Our project focuses on the regulatory properties of a subset of microbiota-specific TR1-like regulatory T (Treg) cells, for which we have al...
2023-04-28 - 2027-04-30 | Financiado
UltiMalVax: A Vaccine Targeting Eradication of Malaria EUROPEAN VACCINE INITIATIVE E.V tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Malaria killed about 640 thousand people in 2020, largely young children in Africa. Rapid recent progress has led to two anti-sporozoite vac...
2023-04-21 - 2027-04-30 | Financiado
IMMUTOL: ADVANCED ANTIGEN-SPECIFIC DENDRITIC CELL-BASED THERAPY TO RE-ESTABLISH TOLERANCE IN IMMUNE-MEDIATED... FONDAZIONE TELETHON ETS tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Autoimmune diseases are currently treated with immunosuppressive and supportive therapies, which dampen inflammation, but do not stop the ca...
2023-04-14 - 2027-04-30 | Financiado
DREAMS: Drug REpurposing with Artificial intelligence for Muscular disorderS CENTRE DETUDE DES CELLULES SOUCHES tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage According to World Health Organization, to date, fewer than 6% of rare diseases (RDs) have an approved treatment option. In the light of thi...
2023-10-08 - 2028-10-31 | Financiado
FIBROTARGET: Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseases KATHOLIEKE UNIVERSITEIT LEUVEN tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Fibrostenosis is the driving reason for the persistent need in bowel resections in inflammatory bowel diseases (IBD). Current IBD therapies...
2023-04-24 - 2028-03-31 | Financiado
PHOENIX: NANOMEDICINE FOR ORGAN TRANSPLANTATION TOLERANCE (PHOENIX) ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage PROBLEM: Today, organ transplant medicine is limited by life-long immunosuppression and vulnerability to infections, malignancies and cardio...
2023-03-14 - 2026-03-31 | Financiado
ARTiDe: Autoantigen-specific adoptive regulatory T cell therapy against type 1 diabetes (ARTiDe) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Type 1 diabetes (T1D) is an incurable disease, often starting in childhood, with a risk of devastating complications, premature mortality, a...
2023-04-27 - 2028-06-30 | Financiado
IN-ARMOR: THERAPEUTIC EPIGENETIC ENHANCEMENT OF THE INNATE IMMUNITY TO EFFECTIVELY COMBAT ANTIMICROBIAL RESIS... HASKOLI ISLANDS tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Antimicrobial resistance (AMR) & multi-drug resistance, whereby pathogens evolve to resist antibiotic drugs, is designated by WHO one of the...
2023-05-01 - 2027-04-30 | Financiado
SIMPATHIC: Accelerating drug repurposing for rare neurological, neurometabolic and neuromuscular disorders by e... STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Drug repurposing can fill an important gap for rare disease patient groups with large unmet medical needs. In comparison to traditional drug...
2023-07-01 - 2028-06-30 | Financiado
FLUniversal: Intranasal, rapid-acting vaccine for all seasonal and pandemic influenza viruses Zafiro Business Solutions Korlatolt Felelossegu Tarsasag tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage "Researchers worldwide have been working to develop a universal flu vaccine, but no breakthrough has yet been achieved. FLUniversal is not "...
2023-06-01 - 2027-05-31 | Financiado
BAXERNA 2.0: Immunopeptidomics-based Development of Next-Generation Bacterial mRNA Vaccines VIB VZW tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage BAXERNA 2.0 will establish a new vaccine development pipeline based on dramatically improved immunopeptidomics screening and innovative mRNA...
2023-07-01 - 2028-06-30 | Financiado
EURAS: EUropean network for neurodevelopmental RASopathies UNIVERSITATSKLINIKUM ERLANGEN tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Cardio-facio-cutaneous syndrome, Costello syndrome and SYNGAP1-related encephalopathy are rare neurodevelopmental RASopathies manifesting wi...
2023-06-01 - 2027-05-31 | Financiado
LightCure: LightCure - Light for double specificity and efficacy without burden STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Congenital hyperinsulinism (CHI) is a group of rare diseases of newborns and infants with functionally defective nonneoplastic beta-cells th...
2024-01-01 - 2029-12-31 | Financiado
NOSEVAC: INNOVATIVE NASAL VACCINES TO PREVENT PATHOGEN COLONIZATION AND INFECTION IN THE UPPER RESPIRATORY TR... EUROPEAN VACCINE INITIATIVE E.V tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Bacterial and viral respiratory infections are a leading cause of morbidity and mortality worldwide. Streptococcus pneumoniae and Bordetella...
2023-05-01 - 2028-04-30 | Financiado
OptiViVax: Optimising a High Efficacy Plasmodium vivax Malaria Vaccine STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Plasmodium vivax is the most widespread human malaria with 2.5 billion people living at risk in South America, Oceania and Asia. The revised...
2023-06-01 - 2028-05-31 | Financiado
GEREMY: Gene Therapy for treatment of rare inherited Arrhythmogenic Cardiomyopathy STICHTING NETHERLANDS HEART INSTITUTE tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Development of a cure for rare cardiac diseases is a risky, costly and time-consuming process, which is hampered by insufficient insight int...
2023-05-01 - 2027-04-30 | Financiado
TiilT: Preclinical development of a 3rd-generation interleukin-2 targeted to inflammatory sites SORBONNE UNIVERSITE tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage As major players in the regulation of immune responses, regulatory T cells (Tregs) are important therapeutic targets for autoimmune and infl...
2023-06-01 - 2028-05-31 | Financiado
NEXGEN-PD: Next Generation Vaccine Platform Leveraging Skin Immunity to Provide Disease-Modifying Treatment of... TRIDEM BIOSCIENCE GMBH CO KG tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Parkinson’s Disease (PD) is a major neurodegenerative disorder with no established treatment modalities capable of modifying disease patholo...
2023-04-01 - 2027-03-31 | Financiado
TBVAC-HORIZON: Improving understanding of lung immunity in tuberculosis to establish a diverse, innovative TB vacci... STICHTING TUBERCULOSIS VACCINE INITIATIVE tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Tuberculosis (TB) remains one of the most devastating infectious diseases worldwide, killing over 4,000 people every day. Prevention of tube...
2023-04-01 - 2027-03-31 | Financiado
RESTORE VISION: Novel advanced and repurposed therapeutics for vision restoration in a group of severe rare ocular s... UNIVERSITY OF GALWAY tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-DISEASE-06-two-stage Rare Eye Diseases (REDs) are a major cause of visual impairment and blindness in Europe, affecting patients of all ages. The RESTORE VISION...
2023-05-01 - 2027-04-30 | Financiado